Please login to the form below
UCB’s Mark Bodmer elected to BIA board
Will hold the position for a three-year fixed term
UCB's Mark Bodmer has been elected to the board of UK trade body the BioIndustry Association (BIA).
Bodmer is VP, NewMedicines Therapeutics at UCB, having joined the company in 2012 as head of immunology.
As a board member of the BIA Bodmer will play a role in shaping the policy environment of the UK biotech industry. He will hold the role for three years, starting in January 2015.
Prior to joining UCB Bodmer served as senior VP of immunoinflammation, medicines discovery and development at GlaxoSmithKline.
His background also includes CEO appointments at three start-ups from 1996 to 2007: Hexagen, Lorantis and Biotica.
COVID-19 Updates and Daily News
Featured jobs
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Lead Copywriter
-
Competitive
-
Medical Editor
-
Competitive
-
Healthcare Account Director
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Senior Account Manager
-
Competitive
- PHE study finds people who have had COVID-19 can still transmit the virus
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- Nucleus Global announces a trio of promotions
- PHE study finds people who have had COVID-19 can still transmit the virus
- AZ seeks EU approval for its Oxford University-partnered COVID-19 vaccine
- Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
- Lilly’s antibody bamlanivimab cuts COVID-19 risk by up to 80%
- Gilead’s Jyseleca is given a NICE recommendation for rheumatoid arthritis
- Janet Woodcock named acting commissioner of the FDA
- Lateral flow tests detect ‘most infectious’ COVID-19 cases, Oxford researchers find
- 3 reasons why clinical trials will thrive in 2021
- #DemandDiversity: New research on COVID-19 clinical trial perceptions within minorities and high-risk populations
PMHub
W2O Group
W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...
Latest intelligence
- 3 reasons why clinical trials will thrive in 2021
- It’s not often that a single event can change the trajectory of an entire system, yet that is exactly what has happened to healthcare systems across the world and clinical...
- #DemandDiversity: New research on COVID-19 clinical trial perceptions within minorities and high-risk populations
- Lack of diversity in clinical trials still remains on of the biggest issues for COVID-19 clinical trials. But despite the growing discussions, calls for change, growing regulatory guidance and much...
- The pandemic preparedness paradox
- Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Quick links
Infographics
